Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

"Dual-lock"-controlled activatable nanotheranostics for chemiluminescence resonance energy transfer (CRET)-driven enhanced photoimmunotherapy.

Journal of materials chemistry. B·2026
Same author

Proteomic analysis reveals lipid metabolism disruption and key targets in ARPE-19 cells after RNF13 knockdown.

Scientific reports·2026
Same author

Tumor microenvironment-adaptive nanocatalysts: harnessing pH gradients for selective and synergistic cancer therapy.

Journal of materials chemistry. B·2026
Same author

Cerebrovascular Imaging-to-Graph Reconstruction for Individualized Digital Twin Brains.

bioRxiv : the preprint server for biology·2026
Same author

Dual-quenched and redox-responsive gold nanoplatforms for tumor-specific multimodal theranostics.

Nanoscale·2026
Same author

Targeting NOX4 with Quercetagetin-PLGA nanomaterials: a novel therapeutic strategy for Alzheimer's disease.

Naunyn-Schmiedeberg's archives of pharmacology·2026

Related Experiment Video

Updated: Jul 12, 2026

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
06:11

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

Plasma Sphingolipid Profiling Predicts Radiosensitivity in Hepatocellular Carcinoma.

Xiang Yuan1, Kai Wang2, Fengxin Chen3

  • 1Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, People's Republic of China.

Journal of Hepatocellular Carcinoma
|March 4, 2026
PubMed
Summary

Plasma sphingolipids can predict hepatocellular carcinoma (HCC) radiosensitivity. Lower S1P and higher ceramides indicate better response, enabling precision radiotherapy for HCC patients.

Keywords:
biomarkerliquid chromatography-tandem mass spectrometrypredictive modelradiotherapy

More Related Videos

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Advancements in the Metabolic Profiling of Three-Dimensional Brain Tumor Spheroids for Drug Screening
06:50

Advancements in the Metabolic Profiling of Three-Dimensional Brain Tumor Spheroids for Drug Screening

Published on: September 5, 2025

Related Experiment Videos

Last Updated: Jul 12, 2026

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
06:11

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Advancements in the Metabolic Profiling of Three-Dimensional Brain Tumor Spheroids for Drug Screening
06:50

Advancements in the Metabolic Profiling of Three-Dimensional Brain Tumor Spheroids for Drug Screening

Published on: September 5, 2025

Area of Science:

  • Oncology
  • Metabolomics
  • Biomarker Discovery

Background:

  • Radiotherapy is crucial for hepatocellular carcinoma (HCC) but limited by radioresistance.
  • Sphingolipids are bioactive lipids linked to treatment resistance via metabolic reprogramming.
  • Circulating sphingolipids as non-invasive biomarkers for HCC radiosensitivity are unexplored.

Purpose of the Study:

  • To investigate circulating sphingolipids as non-invasive biomarkers for predicting radiotherapy response in HCC patients.
  • To identify specific sphingolipid profiles associated with radiosensitivity in HCC.
  • To develop predictive models integrating sphingolipids and clinical factors.

Main Methods:

  • Prospective study of 61 HCC patients undergoing radiotherapy.
  • LC-MS/MS analysis of pre-treatment plasma sphingolipids.
  • Development and validation of predictive models using logistic regression, LASSO, and AUC analysis.

Main Results:

  • Objective response rate was 54.1%.
  • Responders showed lower S1P and higher ceramides (CER(d18:1/20:0), CER(d18:1/24:1)).
  • Integrated models incorporating S1P, ceramides, ALP, and TBIL achieved high predictive accuracy (AUC=0.930).

Conclusions:

  • Baseline plasma sphingolipid profiles predict HCC radiosensitivity.
  • Findings support the 'sphingolipid rheostat' theory and guide precision radiotherapy.
  • Establishes a framework for sphingolipid-guided treatment and future validation trials.